Skip to main content

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  265.01
+5.67 (2.19%)
AAPL  302.25
+3.28 (1.10%)
AMD  447.58
+33.53 (8.10%)
BAC  51.23
+0.53 (1.05%)
GOOG  384.90
+0.00 (0.00%)
META  605.06
+2.45 (0.41%)
MSFT  421.06
+3.64 (0.87%)
NVDA  223.47
+2.86 (1.30%)
ORCL  188.16
+6.70 (3.69%)
TSLA  417.26
+13.15 (3.25%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.